Biotech RadarJobs updated

COMPANY

Sagimet Biosciences

sagimet.com ↗ · West Coast

Clinical Phase 3

5 open jobs · last seen Oct 23, 2026 · 14 sources

Keywords: metabolic MASH NASH Metabolic Dysfunction-Associated Steatohepatitis Nonalcoholic Steatohepatitis Nonalcoholic Fatty Liver Acne Vulgaris Acne MASLD Metabolic Dysfunction-Associated Steatotic Liver Disease Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) Non-alcoholic Steatohepatitis Hepatic Impairment Cirrhosis Denifanstat TVB-2640 TVB-3567

Profile checked Oct 10, 2026

5Open jobs$290.0MRaised (2 yrs)10Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Senior Medical WriterSAGIMET HYBRIDSep 22, 2026Oct 16, 2026
Administrative AssistantSAGIMET HYBRIDAug 18, 2026Oct 16, 2026
Senior Director, QualitySAGIMET HYBRIDAug 14, 2026Oct 16, 2026
Senior Medical DirectorSAGIMET HYBRIDJul 20, 2026Oct 16, 2026
Vice President, Regulatory and Head of Regulatory AffairsSAGIMET HYBRIDMay 20, 2026Oct 16, 2026

See all 5 jobs

Timeline

  1. Raise Follow-on offering: $115M (total, as published), announced Oct 1, 2026. Source: company release on GlobeNewswire. source ↗
  2. Trial start 3: Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne source ↗
  3. Partnership Partnership / licensing announced Sep 30, 2026. Source: SEC filing. source ↗
  4. Raise Follow-on offering: $175M (total, as published), announced Apr 27, 2026. Source: company release on GlobeNewswire. source ↗
  5. Partnership Partnership / licensing announced Dec 17, 2025. Source: SEC filing. source ↗
  6. Trial start Phase 1: A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants source ↗
  7. Trial start 1: Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne source ↗
  8. Trial start 3: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH source ↗
  9. Trial start 3: A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis source ↗
  10. Trial start I: A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function source ↗
  11. Trial start Phase 1: Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects source ↗
  12. Trial start Phase 2: Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH) source ↗
  13. Trial start Phase 2: Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH) source ↗
  14. Trial start 1: A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $290.0M. Last 2 years.

Clinical trials (lead sponsor) 10

RecordTitlePhaseStatusStartPrimary completion
NCT07863193Phase 3 Study of Denifanstat in Participants With Moderate to Severe Acne3Recruiting2026-102027-08 (estimated)
NCT06989840Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne1RecruitingJun 3, 20252027-01 (estimated)
NCT07216313A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult ParticipantsPhase 1CompletedSep 30, 2025Oct 20, 2025 (actual)
NCT06692283A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH3Withdrawn2025-032026-06 (estimated)
NCT06594523A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis3Withdrawn2025-032030-12 (estimated)
NCT04906421Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)Phase 2CompletedAug 12, 2021Oct 2, 2023 (actual)
NCT03938246Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)Phase 2CompletedMar 22, 2019Oct 2, 2021 (actual)
NCT05835180A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic FunctionICompletedMay 1, 2023Dec 18, 2023 (actual)
NCT05657834Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male SubjectsPhase 1CompletedNov 21, 2022Dec 21, 2022 (actual)
NCT02223247A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors1Completed2013-112017-06 (actual)

Open jobs 5

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Senior Medical WriterSAGIMET HYBRIDSep 22, 2026Oct 16, 2026Senior
Administrative AssistantSAGIMET HYBRIDAug 18, 2026Oct 16, 2026Mid
Senior Director, QualitySAGIMET HYBRIDAug 14, 2026Oct 16, 2026Senior
Senior Medical DirectorSAGIMET HYBRIDJul 20, 2026Oct 16, 2026Senior
Vice President, Regulatory and Head of Regulatory AffairsSAGIMET HYBRIDMay 20, 2026Oct 16, 2026Executive

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Feedback